Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas
Abstract Oligodendrogliomas are a distinct subtype of diffuse gliomas characterized by IDH mutations and 1p/19q codeletion, classified as grade 2 or 3 based on histological features. This review examines current advancements in the diagnosis, treatment, and prognosis of oligodendrogliomas, with an e...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02815-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231210779869184 |
|---|---|
| author | Jing Bao Zhenjiang Pan Shepeng Wei |
| author_facet | Jing Bao Zhenjiang Pan Shepeng Wei |
| author_sort | Jing Bao |
| collection | DOAJ |
| description | Abstract Oligodendrogliomas are a distinct subtype of diffuse gliomas characterized by IDH mutations and 1p/19q codeletion, classified as grade 2 or 3 based on histological features. This review examines current advancements in the diagnosis, treatment, and prognosis of oligodendrogliomas, with an emphasis on personalized approaches driven by molecular insights. Surgery remains the cornerstone of treatment, aiming for maximal safe resection to obtain tissue for diagnosis and alleviate symptoms. For grade 2 tumors with residual disease but no symptomatic progression, the IDH inhibitor vorasidenib has emerged as a promising option to delay the need for radiation therapy (RT) and chemotherapy. For grade III oligodendrogliomas, postoperative combined-modality therapy with RT and chemotherapy, such as the PCV regimen, demonstrates significant survival benefits, while temozolomide is an alternative due to its ease of administration and reduced toxicity. Recurrent oligodendrogliomas present therapeutic challenges, necessitating tailored strategies based on prior treatments and the interval since initial therapy. Options include repeat surgery, reirradiation, or novel targeted therapies. Advances in molecular diagnostics, such as homozygous CDKN2A/B deletion as a prognostic marker, have refined risk stratification and informed treatment decisions. Despite these strides, further research is needed to optimize long-term outcomes and address resistance mechanisms. This review underscores the importance of integrating molecular diagnostics with clinical management to achieve personalized, evidence-based care for patients with oligodendrogliomas. |
| format | Article |
| id | doaj-art-8f57039377aa4d2dba2363f10091ffe0 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-8f57039377aa4d2dba2363f10091ffe02025-08-20T02:03:36ZengSpringerDiscover Oncology2730-60112025-05-0116112210.1007/s12672-025-02815-6Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasJing Bao0Zhenjiang Pan1Shepeng Wei2Department of Neurosurgery, Shidong HospitalDepartment of Neurosurgery, Shidong HospitalDepartment of Neurosurgery, Shidong HospitalAbstract Oligodendrogliomas are a distinct subtype of diffuse gliomas characterized by IDH mutations and 1p/19q codeletion, classified as grade 2 or 3 based on histological features. This review examines current advancements in the diagnosis, treatment, and prognosis of oligodendrogliomas, with an emphasis on personalized approaches driven by molecular insights. Surgery remains the cornerstone of treatment, aiming for maximal safe resection to obtain tissue for diagnosis and alleviate symptoms. For grade 2 tumors with residual disease but no symptomatic progression, the IDH inhibitor vorasidenib has emerged as a promising option to delay the need for radiation therapy (RT) and chemotherapy. For grade III oligodendrogliomas, postoperative combined-modality therapy with RT and chemotherapy, such as the PCV regimen, demonstrates significant survival benefits, while temozolomide is an alternative due to its ease of administration and reduced toxicity. Recurrent oligodendrogliomas present therapeutic challenges, necessitating tailored strategies based on prior treatments and the interval since initial therapy. Options include repeat surgery, reirradiation, or novel targeted therapies. Advances in molecular diagnostics, such as homozygous CDKN2A/B deletion as a prognostic marker, have refined risk stratification and informed treatment decisions. Despite these strides, further research is needed to optimize long-term outcomes and address resistance mechanisms. This review underscores the importance of integrating molecular diagnostics with clinical management to achieve personalized, evidence-based care for patients with oligodendrogliomas.https://doi.org/10.1007/s12672-025-02815-6IDH-mutant oligodendrogliomas1p/19q codeletionMolecular diagnosticsPersonalized therapyPrognostic markers |
| spellingShingle | Jing Bao Zhenjiang Pan Shepeng Wei Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas Discover Oncology IDH-mutant oligodendrogliomas 1p/19q codeletion Molecular diagnostics Personalized therapy Prognostic markers |
| title | Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas |
| title_full | Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas |
| title_fullStr | Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas |
| title_full_unstemmed | Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas |
| title_short | Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas |
| title_sort | unlocking new horizons advances in treating idh mutant 1p 19q codeleted oligodendrogliomas |
| topic | IDH-mutant oligodendrogliomas 1p/19q codeletion Molecular diagnostics Personalized therapy Prognostic markers |
| url | https://doi.org/10.1007/s12672-025-02815-6 |
| work_keys_str_mv | AT jingbao unlockingnewhorizonsadvancesintreatingidhmutant1p19qcodeletedoligodendrogliomas AT zhenjiangpan unlockingnewhorizonsadvancesintreatingidhmutant1p19qcodeletedoligodendrogliomas AT shepengwei unlockingnewhorizonsadvancesintreatingidhmutant1p19qcodeletedoligodendrogliomas |